Literature DB >> 20543565

Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer.

Nada H Khattar1, Sarah P Coe-Atkinson, Arnold J Stromberg, James R Jett, Edward A Hirschowitz.   

Abstract

Autoantibody profiling is a developing approach that incorporates immune recognition of myriad aberrant cancer proteins into a single diagnostic assay. We have previously described methodology to screen T7-phage NSCLC-cDNA libraries for phage-expressed proteins recognized by NSCLC-associated antibodies, and developed a multiplex assay that has excellent ability to discriminate NSCLC from control samples. This follow-up report describes the development and testing of a diagnostic autoantibody assay that uses seven amino-acid peptides as capture proteins. A random-peptide M13-phage library was screened for proteins recognized by cancer-associated antibodies. One hundred twenty-one NSCLC case and control samples were divided into two groups for training and validation, or alternately, evaluated sequentially in a leave-one-out analysis. Candidate antibody-markers were ranked by statistical discrimination between cases and controls. Receiver-Operating-Characteristic (ROC-AUC) suggested the predictive potential of various marker combinations. A five-marker combination (AUC = 0.982) afforded 90% sensitivity and 73% specificity in a training-and-testing strategy. Leave-one-out validation provided similar class prediction. Data confirm the potential of antibody profiling to provide high levels of cancer prediction. Random peptide libraries offer a universal source of capture proteins for antibody profiling that obviates the need for tumor-specific library construction and abrogates inherent problems with tumor heterogeneity during biomarker discovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543565      PMCID: PMC3040837          DOI: 10.4161/cbt.10.3.12395

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

1.  Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets.

Authors:  E W Steyerberg; M J Eijkemans; F E Harrell; J D Habbema
Journal:  Med Decis Making       Date:  2001 Jan-Feb       Impact factor: 2.583

2.  Multivariable analysis: a primer for readers of medical research.

Authors:  Mitchell H Katz
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

3.  Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis.

Authors:  C Lombardi; G F Tassi; G Pizzocolo; F Donato
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

4.  Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries.

Authors:  M Sioud; M H Hansen
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

Review 5.  Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.

Authors:  M Abu-Shakra; D Buskila; M Ehrenfeld; K Conrad; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 6.  Clinical relevance of molecular markers in lung cancer.

Authors:  P Iyengar; M-S Tsao
Journal:  Surg Oncol       Date:  2002-12       Impact factor: 3.279

7.  Screening for lung cancer with low-dose spiral computed tomography.

Authors:  Stephen J Swensen; James R Jett; Jeff A Sloan; David E Midthun; Thomas E Hartman; Anne-Marie Sykes; Gregory L Aughenbaugh; Frank E Zink; Shauna L Hillman; Gayle R Noetzel; Randolph S Marks; Amy C Clayton; Peter C Pairolero
Journal:  Am J Respir Crit Care Med       Date:  2002-02-15       Impact factor: 21.405

8.  Autoantigen microarrays for multiplex characterization of autoantibody responses.

Authors:  William H Robinson; Carla DiGennaro; Wolfgang Hueber; Brian B Haab; Makoto Kamachi; Erik J Dean; Sylvie Fournel; Derek Fong; Mark C Genovese; Henry E Neuman de Vegvar; Karl Skriner; David L Hirschberg; Robert I Morris; Sylviane Muller; Ger J Pruijn; Walther J van Venrooij; Josef S Smolen; Patrick O Brown; Lawrence Steinman; Paul J Utz
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

9.  Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection.

Authors:  S Tanguay; L R Bégin; M M Elhilali; H Behlouli; P I Karakiewicz; A G Aprikian
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

10.  Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.

Authors:  O L Ozdal; A G Aprikian; L R Bégin; H Behlouli; S Tanguay
Journal:  BJU Int       Date:  2004-05       Impact factor: 5.588

View more
  11 in total

1.  Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer.

Authors:  Liping Dai; Jitian Li; Jun-Chieh J Tsay; Ting-An Yie; John S Munger; Harvey Pass; William N Rom; Eng M Tan; Jian-Ying Zhang
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

Review 2.  The state of molecular biomarkers for the early detection of lung cancer.

Authors:  Mohamed Hassanein; J Clay Callison; Carol Callaway-Lane; Melinda C Aldrich; Eric L Grogan; Pierre P Massion
Journal:  Cancer Prev Res (Phila)       Date:  2012-06-11

Review 3.  Research status and funding trends of lung cancer biomarkers.

Authors:  Cui Li; Wei Hong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 4.  Advances in proteomic strategies toward the early detection of lung cancer.

Authors:  Mohamed Hassanein; Jamshedur S M Rahman; Pierre Chaurand; Pierre P Massion
Journal:  Proc Am Thorac Soc       Date:  2011-05

5.  The MethDet: a technology for biomarker development.

Authors:  Victor V Levenson; Anatoliy A Melnikov
Journal:  Expert Rev Mol Diagn       Date:  2011-11       Impact factor: 5.225

6.  Peptides from the variable region of specific antibodies are shared among lung cancer patients.

Authors:  Dominique de Costa; Ingrid Broodman; Wim Calame; Christoph Stingl; Lennard J M Dekker; René M Vernhout; Harry J de Koning; Henk C Hoogsteden; Peter A E Sillevis Smitt; Rob J van Klaveren; Theo M Luider; Martijn M Vanduijn
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

7.  Serum unsaturated free Fatty acids: potential biomarkers for early detection and disease progression monitoring of non-small cell lung cancer.

Authors:  Yaping Zhang; Chengyan He; Ling Qiu; Yanmin Wang; Li Zhang; Xuzhen Qin; Yujie Liu; Dan Zhang; Zhili Li
Journal:  J Cancer       Date:  2014-09-19       Impact factor: 4.207

Review 8.  Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.

Authors:  Zhen-Ming Tang; Zhou-Gui Ling; Chun-Mei Wang; Yan-Bin Wu; Jin-Liang Kong
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

Review 9.  Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review.

Authors:  Bin Yang; Xiaoyan Li; Tianyi Ren; Yiyu Yin
Journal:  Cell Death Discov       Date:  2019-08-05

10.  Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts.

Authors:  Kourtney Trudgen; Nada H Khattar; Eric Bensadoun; Susanne Arnold; Arnold J Stromberg; Edward A Hirschowitz
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.